Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
about
Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange.Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stentingLife-threatening thrombotic thrombocytopenic purpura associated with dental foci. Report of two cases.Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience.Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review.Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patientsRituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndromeDisseminated carcinoma diagnosed by bone marrow biopsy in patients with microangiopathic hemolytic anemia and thrombocytopenia: a report of two cases with gastric cancer and a review of the literature.Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center.Retrospective review of 25 cases of thrombotic thrombocytopenic purpura in Pakistan.Indicators of acute and persistent renal damage in adult thrombotic microangiopathy.Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies.Tacrolimus-induced thrombotic microangiopathy in orthotopic liver transplant patients: case series of four patients.Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.Acute Progression of Adult-Onset Atypical Hemolytic-Uremic Syndrome due to CFH Mutation: A Case Report.Does corticosteroid treatment cause prolonged recovery and increased total bilirubin level in severe ADAMTS-13-deficient TTP patient?Re-examination of 30-day survival and relapse rates in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.A proposal: the need for thrombotic thrombocytopenic purpura Specialist Centres--providing better outcomes.Liver transplantation for aHUS: still needed in the eculizumab era?Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura.Use of cellular and plasma apheresis in the critically ill patient: Part II: Clinical indications and applications.Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy.Diagnosis and management of atypical hemolytic uremic syndrome in children: single centre experience.Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient.
P2860
Q33340211-42C70669-6B4B-4B21-9169-4A2378EB3C78Q33360800-E9DCF84F-C78A-4249-B595-F64511953C3FQ33360967-D8454678-3A0F-4077-B2B1-E1B56EC526D9Q33363278-9D815BE4-818D-4268-9550-F4C9CC85B90AQ33373783-B7D8B865-5F8A-452B-A042-857EFBAAE35DQ33377495-639C030A-5F61-4EAA-9FE0-3C29772B6FCCQ33377727-1F65C598-3004-4B01-A022-92D274A1BE84Q33382221-548394B0-FF9D-4F12-8A1D-633D7A16152EQ33391086-D2B7C14E-D80F-4D5E-998D-BC1279722004Q33391765-FEC65620-DB2E-459E-8165-EA25BAF99D95Q33394558-B14FD27C-A470-4C19-9B07-1A1174DC513AQ33399210-302C4C58-6068-4F0D-AFBF-D05C84BCDC5AQ33399411-94FA8967-4E95-408C-9836-A116A9865FEEQ33401197-8B3120A9-6430-4159-838F-E7747E1A49FFQ33401647-D829CA21-E895-442D-850F-68D2F221DFE8Q33403749-1BA45CA9-027D-47EF-9813-AC01F0CDE636Q33406097-4028BC76-89E5-4DFF-9409-6AD29613361AQ33407597-71613130-2A49-41A9-85A8-F506E1B96B73Q33413460-4EC81744-0DC6-44F4-B7F7-2DEBFE91F575Q33419716-81B96C0D-139E-45CD-93D4-5FC61FA29D36Q33423051-27377A37-9D21-40F7-90DE-BD9FC253AE8FQ33423846-5717B377-237F-4890-989C-CA687D9A2AB9Q33427846-3DD7D20C-B751-41C4-AB7E-292272275C48Q33435833-242BD8D9-A2C0-43BA-BAEC-A1C3260AD770Q36108261-DA3AE9A4-03F4-4A09-A188-544329FB2E76Q39021138-5B15D61A-9DC0-4D98-A1F0-1BC3F104DCBFQ41892604-0B88FC79-555C-424E-936E-AB389EB94BE9Q48286980-E7E33EE9-33A3-47C8-B2BD-64C55E7EE603
P2860
Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Improved survival with plasma ...... ura-hemolytic uremic syndrome.
@ast
Improved survival with plasma ...... ura-hemolytic uremic syndrome.
@en
Improved survival with plasma ...... ura-hemolytic uremic syndrome.
@nl
type
label
Improved survival with plasma ...... ura-hemolytic uremic syndrome.
@ast
Improved survival with plasma ...... ura-hemolytic uremic syndrome.
@en
Improved survival with plasma ...... ura-hemolytic uremic syndrome.
@nl
prefLabel
Improved survival with plasma ...... ura-hemolytic uremic syndrome.
@ast
Improved survival with plasma ...... ura-hemolytic uremic syndrome.
@en
Improved survival with plasma ...... ura-hemolytic uremic syndrome.
@nl
P2093
P1476
Improved survival with plasma ...... ura-hemolytic uremic syndrome.
@en
P2093
P304
P356
10.1016/S0002-9343(99)00286-7
P407
P577
1999-12-01T00:00:00Z